3D & 4D Printing Methods for Pharmaceutical Manufacturing and Personalised Drug Delivery Opportunities and Challenges /
New materials and manufacturing techniques are emerging with potential to address the challenges associated with the manufacture of pharmaceutical systems that will teach new tricks to old drugs. 3D printing (3DP) is a technique that can used for the manufacturing of dosage forms, and especially tar...
保存先:
| 団体著者: | |
|---|---|
| その他の著者: | |
| フォーマット: | 電子媒体 eBook |
| 言語: | 英語 |
| 出版事項: |
Cham :
Springer International Publishing : Imprint: Springer,
2023.
|
| 版: | 1st ed. 2023. |
| シリーズ: | AAPS Introductions in the Pharmaceutical Sciences,
11 |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1007/978-3-031-34119-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-34119-9 | ||
| 003 | DE-He213 | ||
| 005 | 20260909135154.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 230804s2023 sz | o |||| 0|eng d | ||
| 020 | |a 9783031341199 |9 978-3-031-34119-9 | ||
| 024 | 7 | |a 10.1007/978-3-031-34119-9 |2 doi | |
| 050 | 4 | |a RS400-431 | |
| 072 | 7 | |a PSB |2 bicssc | |
| 072 | 7 | |a SCI013040 |2 bisacsh | |
| 072 | 7 | |a PNB |2 thema | |
| 082 | 0 | 4 | |a 615.19 |2 23 |
| 245 | 1 | 0 | |a 3D & 4D Printing Methods for Pharmaceutical Manufacturing and Personalised Drug Delivery |h [electronic resource] : |b Opportunities and Challenges / |c edited by Dimitrios Lamprou. |
| 250 | |a 1st ed. 2023. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2023. | |
| 300 | |a 1 online resource (XIII, 321 p. 50 illus.). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of colour is Not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background colour |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All Non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a AAPS Introductions in the Pharmaceutical Sciences, |x 2522-8358 ; |v 11 | |
| 505 | 0 | |a 3D and 4D printing in digital healthcare -- 3D Printing for Novel Dosage Form Design -- 3D Printing and regulatory considerations -- Printability of Pharmaceutical Polymers: Issues & Solutions -- Quality by Design (QbD) approach for individualized products based on additive manufacturing,- Material Properties and Selections for Additive Manufacturing (AM) -- Preformulation of 3D printable pharmaceutical dosage forms -- Vat photopolymerization Methods for Drug Delivery Applications -- Extrusion-based 3D printing methods for oral solid dosage forms -- Binder Jetting 3D Printing in Pharmaceutical Manufacturing -- Powder bed fusion 3D printing in drug delivery -- Bioprinting in Personalised Medications -- Shape memory materials and 4D printing in pharmaceutics -- Characterisation methods of final printed products. | |
| 520 | |a New materials and manufacturing techniques are emerging with potential to address the challenges associated with the manufacture of pharmaceutical systems that will teach new tricks to old drugs. 3D printing (3DP) is a technique that can used for the manufacturing of dosage forms, and especially targeting paediatric and geriatric formulations, as permits the fabrication of high degrees of complexity with great reproducibility, in a fast and cost-effective fashion, and offers a new paradigm for the direct manufacture of personalised dosage forms. The book is covering the basics behind each additive manufacturing (AM) method, current applications in pharmaceutics for each 3DP method, and case studies (examples) from a teaching perspective, targeting undergraduate (UG) and postgraduate (PG) students. A unique to this book is the integration of studies based upon the use of different AM technologies, which designed to reinforce importance printing parameters and material considerations. The book includes case studies or multiple-choice questions (MCQs), which allow application of the content in a flipped-classroom. | ||
| 532 | 8 | |a Accessibility summary: This PDF does Not fully comply with PDF/UA standards but does include limited screen reader support, descriptions for Non-text content (such as images and graphs), bookmarks for easy navigation, and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognise the importance of accessibility and welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us via https://www.springernature.com/gp/info/accessibility | |
| 532 | 8 | |a Inaccessible, or known limited accessibility | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Pharmaceutics. |
| 650 | 2 | 4 | |a Structure-Based Drug Design. |
| 650 | 2 | 4 | |a Pharmacology. |
| 700 | 1 | |a Lamprou, Dimitrios. |e editor. |0 (orcid)0000-0002-8740-1661 |1 https://orcid.org/0000-0002-8740-1661 |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031341182 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031341205 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031341212 |
| 830 | 0 | |a AAPS Introductions in the Pharmaceutical Sciences, |x 2522-8358 ; |v 11 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-34119-9 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||